These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36720803)

  • 1. A Cost-Effectiveness Analysis of Biomarkers for Risk Prediction in Atrial Fibrillation.
    Nakhlé G; Tardif JC; Roy D; Rivard L; Samuel M; Dubois A; LeLorier J
    Mol Diagn Ther; 2023 May; 27(3):383-394. PubMed ID: 36720803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk.
    Kawakami H; Nolan MT; Phillips K; Scuffham PA; Marwick TH
    Am Heart J; 2021 Jan; 231():110-120. PubMed ID: 32822655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.
    Nguyen E; Egri F; Mearns ES; White CM; Coleman CI
    Pharmacotherapy; 2016 May; 36(5):488-95. PubMed ID: 27015873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.
    Dong SJ; Wu B; Zhai SD; Zhang YJ; Chu YB; Gupta P; Li YH
    Clin Ther; 2020 Jan; 42(1):144-156.e1. PubMed ID: 31932080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of left atrial appendage closure with Watchman for non-valvular atrial fibrillation patients in Japan.
    Kamae I; Zhong Y; Hara H; Inoue K; Yasaka M; Reddy VY; Holmes DR; Sakurai M; Gavaghan MB; Amorosi SL; McGovern AM; Priest V; Inoue S; Shibahara H; Akehurst RL
    J Med Econ; 2023; 26(1):1357-1367. PubMed ID: 37819734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US.
    Elkind MSV; Witte KK; Kasner SE; Sawyer LM; Grimsey Jones FW; Rinciog C; Tsintzos S; Rosemas SC; Lanctin D; Ziegler PD; Reynolds MR
    BMC Cardiovasc Disord; 2023 Jan; 23(1):45. PubMed ID: 36698055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
    Kansal AR; Sharma M; Bradley-Kennedy C; Clemens A; Monz BU; Peng S; Roskell N; Sorensen SV
    Thromb Haemost; 2012 Oct; 108(4):672-82. PubMed ID: 22898892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of insertable cardiac monitors for the detection of atrial fibrillation in patients with cryptogenic stroke in the United States is cost-effective.
    Maervoet J; Bossers N; Borge RP; Hilpert ST; van Engen A; Smala A
    J Med Econ; 2019 Nov; 22(11):1221-1234. PubMed ID: 31480905
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy.
    Regier DA; Sunderji R; Lynd LD; Gin K; Marra CA
    CMAJ; 2006 Jun; 174(13):1847-52. PubMed ID: 16785459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
    Shah A; Shewale A; Hayes CJ; Martin BC
    Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis.
    Shiffman D; Perez MV; Bare LA; Louie JZ; Arellano AR; Devlin JJ
    BMC Cardiovasc Disord; 2015 Sep; 15():104. PubMed ID: 26419225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.
    Dorian P; Kongnakorn T; Phatak H; Rublee DA; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Lip GY
    Eur Heart J; 2014 Jul; 35(28):1897-906. PubMed ID: 24513791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
    Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
    Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
    Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
    Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.
    Åkerborg Ö; Nilsson J; Bascle S; Lindgren P; Reynolds M
    Clin Ther; 2012 Aug; 34(8):1788-802. PubMed ID: 22770643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles.
    Wang CY; Pham PN; Thai TN; Brown JD
    Pharmacoeconomics; 2020 Dec; 38(12):1333-1343. PubMed ID: 32924092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.